**AMENDMENTS TO THE CLAIMS**

1-2.    (canceled)

3.    (currently amended)  A peptide according to ~~claim 1~~ claim 13 having the formula:

(cyclo 31-34)Ac-Pro-Pro-Ile-Ser-Leu-Asp-Leu-Thr-D-Phe-His-Leu-Leu-Arg-Glu-Val-Leu-Glu-Nle-Ala-Arg-Ala-Glu-Gln-Leu-Ala-Gln-Gln-Glu-His-Ser-Lys-Arg-Lys-Leu-Nle-Glu-Ile-Ile-NH$_2$, or

(cyclo 31-34)Ac-Pro-Pro-Ile-Ser-Leu-Asp-Leu-Thr-D-Phe-His-Leu-Leu-Arg-Glu-Val-Leu-Glu-Nle-Ala-Arg-Ala-Glu-Gln-CML-Ala-Gln-Gln-Glu-His-Ser-Lys-Arg-Lys- Leu-Nle-Glu-Ile-CML-NH$_2$; or

(cyclo 31-34)Ac-Pro-Pro-Ile-Ser-Leu-Asp-Leu-Thr-D-Phe-His-Leu-Leu-Arg-Glu-Val-Leu-Glu-Nle-Ala-Arg-Ala-Glu-Gln-CML-Ala-Gln-Gln-Glu-His-Aib-Lys-Arg-Lys- Leu-Nle-Glu-Ile-CML-NH$_2$.

4.    (canceled)

5.    (currently amended)  A CRF cyclic peptide according to ~~claim 1~~ claim 15 having the formula:

Y$_1$-Pro-Pro-R$_6$-Ser-R$_8$-Asp-Leu-R$_{11}$-D-Phe-His-R$_{14}$-Leu-Arg-Glu-R$_{18}$-Leu-R$_{20}$-Nle-R$_{22}$-R$_{23}$-Ala-R$_{25}$-Gln-Leu-Ala-R$_{29}$-Gln-Glu-R$_{32}$-R$_{33}$-R$_{34}$-Arg-R$_{36}$-R$_{37}$-Nle-R$_{39}$-R$_{40}$-R$_{41}$-NH$_2$ wherein Y$_1$ is an acyl group having not more than 7 carbon atoms; R$_{20}$ is Glu or D-Glu; R$_{22}$ is Ala or Thr; R$_{23}$ is Arg or Lys; R$_{29}$ is Gln or Glu; R$_{32}$ is His, ~~D-His,~~ Aib or Ala; R$_{36}$ is Lys or Leu; R$_{37}$ is Leu or CML; R$_{39}$ is Glu or Asp; R$_{40}$ is Ile, CML or Glu; and R$_{41}$ is Ile, Aib or Ala; wherein the remaining variables are as defined in ~~claim 1~~ claim 15.

6.    (currently amended)  A peptide according to ~~claim 1~~ claim 15 wherein R$_{18}$ is Val, R$_{22}$ is Ala, R$_{23}$ is Arg, ~~R$_{24}$ is Ala,~~ R$_{25}$ is Glu, ~~R$_{28}$ is Ala,~~ R$_{39}$ is Glu, and R$_{41}$ is Ile.

7.     (currently amended)  A peptide according to ~~claim 1~~ claim 15 having the following formula, or a nontoxic salt thereof:

(cyclo 31-34)$Y_1$-Pro-Pro-Ile-Ser-Leu-Asp-Leu-Thr-D-Phe-His-Leu-Leu-Arg-Glu-Val-Leu-Glu-Nle-$R_{22}$-$R_{23}$-Ala-Glu-Gln-$R_{27}$-Ala-Gln-Gln-Glu-$R_{32}$-$R_{33}$-Lys-Arg-Lys-Leu-Nle-Glu-$R_{40}$-Ile-NH$_2$ wherein Y$_1$ is an acyl group having not more than 7 carbon atoms; $R_{22}$ is Ala or Thr; $R_{23}$ is Arg or Lys; $R_{27}$ is Leu or CML; $R_{32}$ is His ~~or Aib~~; $R_{33}$ is Ser or Aib; and $R_{40}$ is Ile or CML.

8-10.  (canceled)

11.     (currently amended)  A peptide ~~according to claim 1~~ having the formula:

(cyclo 31-34) Ac-Pro-Pro-Ile-Ser-Leu-Asp-Leu-Thr-D-Phe-His-Leu-Leu-Arg-Glu-Val-Leu-Glu-Nle- Thr-Lys-Ala-Asp-Gln-Leu-Ala-Gln-Gln-Glu-His-Ser-Lys-Arg-Lys-Leu-Nle-Asp-Ile- Ala-NH$_2$; or

(cyclo 31-34)Ac-Pro-Pro-Ile-Ser-Leu-Asp-Leu-Thr-D-Phe-His-Leu-Leu-Arg-Glu-Val-Leu-Glu-Nle-Ala-Arg-Ala-Glu-Gln-CML-Ala-Gln-Gln-Glu-His-Ser-Lys-Arg-Lys- Leu-Nle-Glu-Ile-Ile-NH$_2$; or

(cyclo 31-34)Ac-Pro-Pro-Ile-Ser-Leu-Asp-Leu-Thr-D-Phe-His-Leu-Leu-Arg-Glu-Val-Leu-Glu-Nle-Ala-Arg-Ala-Glu-Gln-Leu-Ala-Gln-Gln-Glu-His-Aib-Lys-Arg-Lys- Leu-Nle-Glu-Ile-Ile-NH$_2$.

12.  (currently amended)  A peptide according to ~~claim 1~~ claim 13 having the formula:

(cyclo 31-34)Ac-Pro-Pro-Ile-Ser-Leu-Asp-Leu-Thr-D-Phe-His-Leu-CML-Arg-Glu-Val-Leu~~CML~~-Glu-Nle-Ala-Arg-Ala-Glu-Gln-Leu-Ala-Gln-Gln-Glu-His-Ser-Lys-Arg-Lys-Leu- Nle-Glu-Ile-Ile-NH$_2$, or

(cyclo 31-34)Ac-Pro-Pro-Ile-Ser-Leu-Asp-Leu-Thr-D-Phe-His-CML-Leu-Arg-Glu-Val-Leu-Glu-Nle-Ala-Arg-Ala-Glu-Gln-Leu-Ala-Gln-Gln-Glu-His-Ser-Lys-Arg-Lys-Leu-Nle-Glu-Ile-Ile-NH$_2$; or

(cyclo 31-34)Ac-Pro-Pro-Ile-Ser-Leu-Asp-Leu-Thr-D-Phe-His-Leu-Leu-Arg-Glu-Val-Leu-Glu-Nle-Ala-Arg-Ala-Glu-Gln-CML-Ala-Gln-Gln-Glu-His-D-Ser-Lys-Arg-Lys-Leu-Nle-Glu-CML-Ile-NH$_2$.

13.    (currently amended)  A 38-residue or 39-residue CRF ~~agonist~~ cyclic peptide, or a nontoxic salt thereof, which binds to CRFR1 with an affinity substantially greater than it binds to CRFR2, which peptide has the following formula:
Y$_1$-Pro-Pro-Ile-Ser-Leu-Asp-Leu-Thr-D-Phe-His-R$_{14}$-R$_{15}$-Arg-R$_{17}$-R$_{18}$-R$_{19}$-Glu-Nle-Ala-Arg-Ala-Glu-Gln-R$_{27}$-Ala-Gln-Gln-Glu-R$_{32}$-R$_{33}$-Lys-Arg-R$_{36}$-R$_{37}$-Nle-Glu-R$_{40}$-R$_{41}$-NH$_2$
wherein Y$_1$ is an acyl group having not more than 15 carbon atoms or is radioiodinated tyrosine; R$_{14}$ is CML or Leu; R$_{15}$ is CML or Leu; R$_{17}$ is Glu or CML; R$_{18}$ is Val or CML; R$_{19}$ is CML or Leu; R$_{27}$ is CML or Leu; R$_{32}$ is ~~Aib,~~His or D-His; R$_{33}$ is Aib, D-Ala, D-Ser or Ser; R$_{36}$ is Lys or CML; R$_{37}$ is CML or Leu; R$_{40}$ is Ile or CML; and R$_{41}$ is Ile or CML; provided that a cyclizing bond exists between Glu in position 31 and Lys in position 34 and provided further that D-ß-(2-napthyl)alanine(D-2Nal) or D-Leu may be substituted for D-Phe.

14.    (currently amended)  A CRF agonist peptide, or a nontoxic salt thereof, which binds to CRFR1 with an affinity substantially greater than it binds to CRFR2, which peptide has the following formula:
(cyclo 31-34) Y$_1$-Pro-Pro-Ile-Ser-Leu-Asp-Leu-Thr-D-Phe-His-Leu-Leu-Arg-Glu-Val-Leu-Glu-Nle-Ala-Arg-Ala-Glu-Gln-Leu-Ala-Gln-Gln-Glu-His-Ser-Lys-Arg-Lys-Leu-Nle-Glu-Ile-Ile-NH$_2$, wherein Y$_1$ is an acyl group having not more ~~than 15 carbon~~ than 7 carbon atoms or is radioiodinated tyrosine, and wherein a cyclizing bond may exist between the side chains of Glu in the 31-position and Lys in the 34-position.

15.    (new) A 38-residue or 39-residue CRFR1 ligand cyclic peptide which binds to CRFR1 with an affinity substantially greater than it binds to CRFR2, which peptide has the following formula, or a nontoxic salt thereof:

(cyclo 31-34)$Y_1$-Pro-Pro-$R_6$-Ser-$R_8$-Asp-Leu-$R_{11}$-D-Phe-His-$R_{14}$-$R_{15}$-Arg-Glu-$R_{18}$-Leu-$R_{20}$-Nle-$R_{22}$-$R_{23}$-Ala-$R_{25}$-Gln-$R_{27}$-Ala-$R_{29}$-Gln-Glu-$R_{32}$-$R_{33}$-$R_{34}$-Arg-$R_{36}$-$R_{37}$-Nle- $R_{39}$-$R_{40}$-$R_{41}$-$NH_2$ wherein $Y_1$ is an acyl group having not more than 7 carbon atoms or is radioiodinated tyrosine; $R_6$ is Ile, Met or Nle; $R_8$ is Leu or Ile; $R_{11}$ is Thr or Ser; $R_{14}$ is CML or Leu; $R_{15}$ is Leu or CML; $R_{18}$ is Val, CML, Nle or Met; $R_{20}$ is Glu or D-Glu; $R_{22}$ is Ala or Thr; $R_{23}$ is Arg or Lys; $R_{25}$ is Asp or Glu; $R_{27}$ is Leu or CML; $R_{29}$ is Gln or Glu; $R_{32}$ is His, Aib, Ala, Gly, Leu, Gln or Glu; $R_{33}$ is Aib or an L- or D-isomer of Ser, Asn, Leu, Ala, CML or Ile; $R_{34}$ is Lys or Orn; $R_{36}$ is Lys or Leu; $R_{37}$ is CML or Leu; $R_{39}$ is Glu or Asp; $R_{40}$ is Ile, CML or Glu; and $R_{41}$ is Ala, Aib or Ile; provided that D-ß-(2-napthyl)alanine(D-2Nal) or D-Leu may be substituted for D-Phe.